BEDFORD, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” o

BEDFORD, Mass. , July 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular")

Chardan Capital analyst Andreas Argyrides maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy a

BEDFORD, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” o

HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy an

Baird analyst Colleen Kusy maintains Ocular Therapeutix (NASDAQ:OCUL) with a Outperform and raise

Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day Transcript

Ocular Therapeutix, Inc. (NASDAQ:OCUL) stock is trading higher on Wednesday as the company prepares

Ocular outlines FDA-aligned AXPAXLI NDA plan for wet AMD by Q4 2026, revises SOL-R study design, and

Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safet

Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safet

Ocular Therapeutix is transitioning into a major player in the retinal disease market with its lead

https://www.sec.gov/ix?doc=/Archives/edgar/data/1393434/000110465926073496/tm2617802d1_8k.htm

BEDFORD, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” o

BEDFORD, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”),

In addition to Ocular leadership, event to feature prominent retinal disease experts Dr. Arshad M. K

Ocular Therapeutix delivers FDA-approved eye therapies and devices, supported by a pipeline targetin

Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting r

BEDFORD, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or

Ocular Therapeutix, Inc. (OCUL) Presents at Bank of America Global Healthcare Conference 2026 Transc

U.S. stock futures down 0.1%, Dole PLC drops 5.9% after missing earning estimates, other stocks also

BEDFORD, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or

RBC Capital analyst Lisa Walter reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Outperform and

Ocular Therapeutix, Inc. (OCUL) Q1 2026 Earnings Call Transcript

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.41 per share versus the Zacks Consens

Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.40) per share which missed the ana

Enrollment underway in SOL-X long-term extension trial in wet AMD for subjects completing two-year f

Ocular Therapeutix (NASDAQ: OCUL) Executive Chairman, President, and CEO Dr. Pravin Dugel said the c

Ocular Therapeutix shares up on positive data for wet AMD treatment. Company focusing on retinal dis

HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy an

Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular"))), an integrated biopharmaceutical company

On March 20, 2026, EyePoint, Inc. (the "Company") filed a complaint against Ocular Therapeut

MDT: -5% | Medtronic Q3 Adj. EPS $1.36 Beats $1.33 Estimate, Sales $9.017B Beat $8.905B Estimate  

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings

  Monday saw 196 companies set new 52-week lows.

  On Friday, 431 companies hit new 52-week lows.

  Companies Reporting Before The Bell • Celsius Holdings (NASDAQ:CELH) is estimated to report quar

  During Wednesday's morning trading, 254 companies set new 52-week highs.